Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Enhancer of activity of nucleic acid analogue

A nucleic acid analog, active technology, applied in the field of drugs for viral hepatitis, prevention or treatment of viral hepatitis, to achieve the effects of enhancing activity, improving poor prognosis, and improving liver reserve function

Inactive Publication Date: 2015-02-25
EA PHARMA CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the combination of PEG interferon and nucleic acid analogs has the effect of preventing the development of resistant virus, but the therapeutic results suggest no difference from the case of interferon alone (see Non-Patent Documents 5-7)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Enhancer of activity of nucleic acid analogue
  • Enhancer of activity of nucleic acid analogue
  • Enhancer of activity of nucleic acid analogue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] Embodiment 1: the joint application effect (1) of nucleic acid analog preparation and activity enhancer of the present invention

[0115] (method)

[0116] Oral administration of isoleucine, leucine, valine after meals in hepatitis B virus-positive patients who are decompensated cirrhotic patients who exhibit hypoalbuminemia despite adequate food intake Branched-chain amino acid preparation リーバクト (registered trademark) granules (Ajinomoto Co., Ltd.) with a weight ratio of 1:2:1.2 (isoleucine: 0.952 g, leucine: 1.904 g, valine: 1.144 g) , 3 times a day, 1 packet each time, and measure the changes of serum albumin value, AST and ALT value every day. The results were divided into 2 groups and analyzed according to the prescription history of the antiviral chemotherapeutic agent lamivudine (product name: Zephacus (registered trademark) tablets, production and sales company: Graxo Sumiscrain Co., Ltd.). The background of the above two groups of patients is shown in Table 1...

Embodiment 2

[0123] Embodiment 2: the joint application effect (2) of nucleic acid analog preparation and activity enhancer of the present invention

[0124] As rivacte granule and / or antiviral agent, administration is selected from lamivudine (Zefix (registered trademark), Graxosum Crain Co.), entecavir hydrate (Barakruud (registered trademark), Bristol Myayer Co., Ltd.) and Pivoad Nucleic acid analog preparations of Fovir (ヘプセラ (registered trademark), ヘプサスミスクライン Co., Ltd.) were used for 3 to 12 months, and the amount of hepatitis B virus in serum was measured by nucleic acid amplification detection in 20 patients with hepatitis B cirrhosis.

[0125] In addition, the above-mentioned 20 patients were patients with liver cirrhosis, and no liver cancer occurred.

[0126] Nucleic acid amplification detection is carried out by either PCR method or TMA method according to the virus amount of the patient (measurement range: 2.6-7.6 log copies / mL (PCR method), 3.7-8.7 LGE / mL (TMA method) ). LGE...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are: an enhancer of the activity of a nucleic acid analogue preparation; and others. Specifically disclosed is an enhancer of the activity of an nucleic acid analogue, which is characterized by comprising at least one branched amino acid selected from isoleucine, leucine and valine or a salt thereof and has an antiviral activity.

Description

technical field [0001] The present invention relates to an activity enhancer of nucleic acid analogues comprising branched-chain amino acids, a preventive or therapeutic agent for viral hepatitis, a drug for viral hepatitis, etc., comprising a combination of branched-chain amino acids and nucleic acid analogues. Background technique [0002] Hepatitis B virus (hereinafter also referred to as "HBV") belongs to the Hepadnaviridae family (Hepadnaviridae) orthohepadnavirus (orthohepadnavirus), is the pathogenic virus of hepatitis B, which is mainly mediated by blood, mother-child (vertical ) and sexual (horizontal) infection. Although the persistent infection lacks subjective symptoms, it causes chronic hepatitis, which gradually progresses to liver fibrosis, cirrhosis, and liver cancer. On the other hand, in the case of hepatitis B virus infection, it is difficult in principle to completely eliminate the virus, and the use of antiviral therapy to reduce the virus together with...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7072A61K31/198A61K31/513A61K31/522A61K31/675A61P1/16A61P31/12A61P31/20A61P43/00
CPCA61K31/675A61K31/513A61K31/7072A61K31/198A61K31/522A61P1/16A61P31/12A61P31/20A61P43/00A61K2121/00
Inventor 惣中一郎
Owner EA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products